GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

The approval was based on data from two late-stage trials showing the drug was superior to nitrofurantoin, the ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...

Novavax reached a settlement with Gavi, the Vaccine Alliance, after t | International vaccine partnership Gavi has ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- -- Evaluation ...

GSK shares are trading cheaply and offering potential passive income. So is this FTSE 100 stock a no-brainer buy for my ...

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...